EMA Authorised: Sylvant (siltuximab) — Recordati Netherlands B.V.

View source ↗

Summary

The European Medicines Agency has authorized Sylvant (siltuximab) for giant lymph node hyperplasia (Castleman disease) with accelerated assessment; the marketin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castleman Disease
• Idiopathic Multicentric Castleman Disease

Drugs mentioned

• Sylvant (siltuximab)

Snippet

Status: Authorised. Therapeutic area: Giant Lymph Node Hyperplasia. MAH: Recordati Netherlands B.V.. Decision date: 24/03/2026. Accelerated assessment